| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 0 | 0 | - | - |
| Research and development | 34,068 | 42,658 | 35,942 | 42,315 |
| General and administrative | 18,351 | 25,020 | 28,446 | 27,109 |
| Restructuring | -172 | 3,471 | - | - |
| Total operating expenses | 52,247 | 71,149 | 64,388 | 69,424 |
| Loss from operations | -52,247 | -71,149 | -64,388 | -69,424 |
| Interest expense | 473 | 473 | 472 | 471 |
| Interest and other income, net | 709 | 483 | 1,336 | 1,327 |
| Accretion of discount on investments, net | 1,679 | 2,220 | 2,190 | 1,849 |
| Net loss | -50,332 | -68,919 | -61,334 | -66,719 |
| Earnings per share, basic, total | -0.45 | -0.62 | -0.56 | -0.71 |
| Earnings per share, diluted, total | -0.45 | -0.62 | -0.56 | -0.71 |
| Weighted average number of shares outstanding, basic, total | 111,571,136 | 111,019,647 | 110,093,461 | 94,158,491 |
| Weighted average number of shares outstanding, diluted, total | 111,571,136 | 111,019,647 | 110,093,461 | 94,158,491 |
ROCKET PHARMACEUTICALS, INC. (RCKT)
ROCKET PHARMACEUTICALS, INC. (RCKT)